Everolimus, a further step in ‘targeted’ antineoplastic therapy?

Everolimus is a representative of a new class of antineoplastic agents offering new therapeutic options even for asyet refractory carcinomas. Alook at the biochemical pathways involved helps understand desired and adverse effects.